Epigenomics AG (FRA:ECX)
Germany · Delayed Price · Currency is EUR 0.9000
0.00 (0.00%)
At close: Sep 18, 2026
Epigenomics AG Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.03 | 0.02 | - | 0.34 | 0.9 | 6.2 | |
Revenue Growth | 172.73% | - | - | -62.29% | -85.51% | 636.70% |
Cost of Revenue | - | - | - | 0.06 | 0.47 | 0.14 |
Gross Profit | 0.03 | 0.02 | - | 0.28 | 0.43 | 6.07 |
Selling, General & Admin | 0.13 | 0.11 | 0.28 | 4.21 | 3 | 7.51 |
Research & Development | - | - | - | - | - | 3.11 |
Other Operating Expenses | 0.21 | 0.29 | 0.9 | -0.32 | 8.8 | -0.39 |
Operating Expenses | 0.35 | 0.41 | 1.19 | 4.46 | 12.15 | 10.23 |
Operating Income | -0.32 | -0.38 | -1.19 | -4.18 | -11.73 | -4.16 |
Interest Expense | - | - | - | - | -0.08 | -0.05 |
Interest & Investment Income | 0.04 | 0.04 | 0.04 | 0.04 | 0.09 | 0.01 |
Currency Exchange Gain (Loss) | -0.02 | -0.02 | 0.02 | -0.09 | 0.72 | 1.82 |
Other Non Operating Income (Expenses) | -0 | - | - | - | -0 | -0.02 |
EBT Excluding Unusual Items | -0.3 | -0.36 | -1.14 | -4.23 | -11 | -2.4 |
Gain (Loss) on Sale of Investments | - | - | -2.28 | -0.23 | -6.31 | - |
Gain (Loss) on Sale of Assets | - | - | - | - | - | -0.01 |
Other Unusual Items | 0.06 | 0.05 | 0.06 | - | - | - |
Pretax Income | -0.24 | -0.31 | -3.35 | -4.46 | -17.3 | -2.41 |
Income Tax Expense | - | - | - | - | - | 0.02 |
Net Income | -0.24 | -0.31 | -3.35 | -4.46 | -17.3 | -2.43 |
Net Income to Common | -0.24 | -0.31 | -3.35 | -4.46 | -17.3 | -2.43 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 1 | 1 | 1 | 1 | 1 | 1 |
Shares Outstanding (Diluted) | 1 | 1 | 1 | 1 | 1 | 1 |
Shares Change | 0.00% | 0.00% | 2.76% | 4.93% | 45.14% | 93.95% |
EPS (Basic) | -0.27 | -0.36 | -3.82 | -5.23 | -21.28 | -4.33 |
EPS (Diluted) | -0.27 | -0.36 | -3.82 | -5.23 | -21.28 | -4.33 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -0.53 | -1.2 | -5.71 | -10.71 | -4.19 |
Free Cash Flow Per Share | - | -0.61 | -1.37 | -6.69 | -13.17 | -7.47 |
Gross Margin | 100.00% | 100.00% | - | 83.19% | 47.27% | 97.81% |
Operating Margin | -1050.00% | -1591.67% | - | -1232.15% | -1304.56% | -67.10% |
Profit Margin | -793.33% | -1308.33% | - | -1316.81% | -1924.80% | -39.14% |
Free Cash Flow Margin | - | -2220.83% | - | -1684.66% | -1191.77% | -67.50% |
EBITDA | - | -0.37 | -1.18 | -2.83 | -4.71 | -4.06 |
EBITDA Margin | - | - | - | - | - | -65.40% |
D&A For EBITDA | - | 0.01 | 0.01 | 1.35 | 7.02 | 0.11 |
EBIT | -0.32 | -0.38 | -1.19 | -4.18 | -11.73 | -4.16 |
EBIT Margin | - | - | - | - | - | -67.10% |